# Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

> **NCT02156739** · NA · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 100 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver and Intrahepatic Bile Duct Disorder
- Metastatic Malignant Neoplasm in the Liver
- Primary Malignant Liver Neoplasm

## Interventions

- **PROCEDURE:** Contrast-enhanced Magnetic Resonance Imaging
- **DRUG:** Gadobutrol
- **DRUG:** Gadoxetate Disodium

## Key facts

- **NCT ID:** NCT02156739
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-10-13
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02156739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02156739, "Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT02156739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*